• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Zealand Pharma A/S

    6/2/22 4:30:46 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email
    6-K 1 tm2217295d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER 

    PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    June 2, 2022

     

     

     

    Commission File Number: 001 - 38178

     

     

     

    Zealand Pharma A/S 

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Sydmarken 11 

    2860 Søborg (Copenhagen)
    Denmark
     

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ¨            Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

     

    Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement Zealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Zealand Pharma A/S
         
      By: /s/ Matthew Dallas
           
        Name: Matthew Dallas
        Title: Chief Financial Officer

     

    Date: June 2, 2022

     

    2

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
         
    99.1   Company announcement – No. 23/ 2022

     

    3

     

    Get the next $ZEAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Zealand Pharma A/S

      15F-12B - Zealand Pharma A/S (0001674988) (Filer)

      9/30/22 5:24:36 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:20:13 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:16:47 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

      Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapiesUnique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenha

      6/18/25 11:29:44 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma increases its share capital as a result of the exercise of employee warrants

      Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

      6/6/25 4:00:00 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

      Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).   The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatme

      6/2/25 1:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care